Details of the Drug

General Information of Drug (ID: DMVE3TK)

Drug Name

Bromocriptine

Synonyms

Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1], [2]

Therapeutic Class

Antiparkinson Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

654.6

Topological Polar Surface Area (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination: 2% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 8 hours [4]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.1866 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.8 mg/mL [3]

Chemical Identifiers

Formula: C32H40BrN5O5
IUPAC Name: (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Canonical SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
InChI: InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
InChIKey: OZVBMTJYIDMWIL-AYFBDAFISA-N

Cross-matching ID

PubChem CID: 31101
ChEBI ID: CHEBI:3181
CAS Number: 25614-03-3
DrugBank ID: DB01200
TTD ID: D06YFA
VARIDT ID: DR00550
INTEDE ID: DR0233
ACDINA ID: D00079

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[7], [8], [9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bromocriptine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Bromocriptine due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[38]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Bromocriptine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[39]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Bromocriptine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Bromocriptine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Pasireotide	DMHM7JS	Moderate	Decreased metabolism of Bromocriptine caused by Pasireotide mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[41]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Bromocriptine due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[42]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Bromocriptine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[43]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Bromocriptine when combined with OPC-34712.	Depression [6A70-6A7Z]	[44]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Bromocriptine and Esketamine.	Depression [6A70-6A7Z]	[45]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Bromocriptine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Bromocriptine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[46]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Bromocriptine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[47]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Bromocriptine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[48]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Bromocriptine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[49]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Bromocriptine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Bromocriptine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Bromocriptine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Bromocriptine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Bromocriptine caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[54]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Bromocriptine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[55]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Bromocriptine when combined with ITI-007.	Insomnia [7A00-7A0Z]	[44]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Bromocriptine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[56]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Bromocriptine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[57]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Bromocriptine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Bromocriptine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Bromocriptine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[59]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Bromocriptine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[60]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Bromocriptine and Lasmiditan.	Migraine [8A80]	[61]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Bromocriptine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[62]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Bromocriptine and Flibanserin.	Mood disorder [6A60-6E23]	[63]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Bromocriptine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[39]
Metoclopramide	DMFA5MY	Moderate	Additive CNS depression effects by the combination of Bromocriptine and Metoclopramide.	Nausea/vomiting [MD90]	[44]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Bromocriptine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[64]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Bromocriptine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[65]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Bromocriptine caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[41]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Bromocriptine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[66]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Bromocriptine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[67]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Bromocriptine when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[44]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Bromocriptine and Quetiapine.	Schizophrenia [6A20]	[44]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Bromocriptine when combined with Aripiprazole.	Schizophrenia [6A20]	[44]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Bromocriptine and Iloperidone.	Schizophrenia [6A20]	[44]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Bromocriptine when combined with Paliperidone.	Schizophrenia [6A20]	[44]
Molindone	DMAH70G	Moderate	Antagonize the effect of Bromocriptine when combined with Molindone.	Schizophrenia [6A20]	[44]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Bromocriptine when combined with Thiothixene.	Schizophrenia [6A20]	[44]
Amisulpride	DMSJVAM	Major	Additive CNS depression effects by the combination of Bromocriptine and Amisulpride.	Schizophrenia [6A20]	[45]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Bromocriptine when combined with Asenapine.	Schizophrenia [6A20]	[44]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Bromocriptine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[68]
LEE011	DMMX75K	Moderate	Decreased metabolism of Bromocriptine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[69]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Bromocriptine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[70]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Bromocriptine when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[71]
-----------


⏷ Show the Full List of 50 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Maleic acid	E00418	444266	Acidulant; Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Edetate disodium	E00186	8759	Complexing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bromocriptine 5 mg capsule	5 mg	Oral Capsule	Oral
Bromocriptine 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Bromocriptine 0.8 mg tablet	0.8 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 35).
2	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44.
8	Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci. 2009 Feb 4;29(5):1538-43.
9	The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol. 1989 Dec;9(6):417-22.
10	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
11	Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
22	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
23	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
24	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
25	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
26	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
27	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
28	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
29	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
30	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
31	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
32	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
33	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
34	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
35	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
36	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
37	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
38	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
41	Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E, Jervell J, Flgstad AK, Djseland O "A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly." J Clin Endocrinol Metab 79 (1994): 461-5. [PMID: 8045964]
42	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
43	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
44	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
45	Cerner Multum, Inc. "Australian Product Information.".
46	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
47	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
48	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
49	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
50	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
51	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
52	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
53	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
54	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
55	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
56	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
57	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
59	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
60	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
61	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
62	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
63	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
64	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
65	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
66	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
67	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
68	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
69	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
70	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
71	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.